about
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis (2007-08-31)A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD)HPV Vaccination Study in Postpartum WomenStudy of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCPROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMALow Impact Laparoscopy vs Standard Laparoscopy During Robot Assisted Radical ProstatectomyA Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCLCytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer TherapyLenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors ProgressionApplying Best Clinical Practices to Patients at High Risk of Respiratory ComplicationsThe CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell CarcinomaPembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDYMicrobiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone MicroarchitectureNeo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility StudyPembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer (HERCULES)Use of an Educational Multimedia Tool Versus Routine Care for the Uptake of Postpartum LARC in High-Risk PregnanciesOvarian Function With ENG Implant and UPA UsePembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsPhase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile InfectionAdjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cmPhase 2 TaxRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeEfficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different LocationsLurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer PatientsLCI-HEM-DRMM-DPEM-001: Phase II Study of Dara-Pembro for Multiple Myeloma Patients With ≥ 3 Prior Lines of TherapyPembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing SurgeryHPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell CarcinomaPembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerStudy on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer PatientsPregnancy in Women With HIV InfectionPembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder CancerLenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney CancerPhase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer
P767
Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung DiseaseA Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)
P859
Q86243264-7F65241B-3450-4305-A913-0B2B0EFE7E12Q86250484-D9E8A32F-6617-40A0-82B4-C64B2FBA7E05Q86255719-684D941D-D84B-49A8-8ED1-BF6A8AB95CCAQ86265319-5C72653C-E442-46D7-A0AC-B0A931498046Q86265715-21ABC192-0BA9-4E8E-9B9A-DD7030A3E9CDQ86267079-479E1200-439D-4240-B260-9DF5E3E4A978Q86284375-18E90D08-A660-4FFB-B724-30CF3E477E8DQ86284721-826FC732-ACDB-4C7E-B9F6-6C73AC61E0D4Q86291605-A0E7B3BA-3BEC-46D0-83C6-34D59B4B2A14Q86295520-30D8D072-C533-44D3-914D-298BC0E332A7Q86301635-A9ACBE35-5A27-4DFA-B3B8-9517456835A2Q86303343-5B6CC5F1-F369-4EF1-A36D-5274B000ECF2Q86308033-48469314-33BA-48BC-9DB4-BE94429A12F8Q86310884-3010C2F8-A8D1-472E-A9A7-307F6F1B6AC6Q86312003-29DA6E11-3C44-40BC-B219-0354A87F8483Q87077109-BA21F1D2-04F9-4D7C-9E91-8384E24F3AC6Q87078692-A765BEFB-D7BA-4E3B-99BB-4A0F3CDDAE1EQ87078697-CE523393-C83D-4266-BA28-3C35ED0EAF8BQ87079181-62DCE482-768C-48B6-8B14-9925878A86A9Q87931305-690A5249-1D9D-4AF2-9602-31A2311B2392Q89155298-C6E0A3EE-B97C-4922-8BE3-4091C96606C8Q89155363-60A0BEA1-CD0E-4838-BA52-C178ECC1E4C7Q90693219-EC86F56B-79DB-48A2-B32C-7CC168AEDA25Q92193655-7BCFAA0D-FB89-40E8-A46C-C80CA4C958F5Q92272006-A5DCC9FB-245B-40C7-A315-F2BC983BA5E3Q92272670-1C00B868-67BA-456A-B97A-1522C38D000DQ92273913-DA686943-C2BB-4A32-93A7-536255444C6AQ93214904-4A78D32F-E22C-408A-BBA3-7D5797734172Q93215063-D47593B6-AD6D-46DF-B7F1-97E6137AC801Q93328822-AF9471F8-3CE3-43AA-981C-C343E8FAC90FQ93476021-F063DA65-815A-4D28-87D8-B7867BE60CACQ93704572-69EAC198-115C-4C74-82A3-C0562E7F21ACQ94234816-F6C54ABA-AEFA-4DEB-B7EE-FEB76A7AE71CQ94934594-A4EF0FCC-12AB-410F-859A-BA7655D5A4CCQ94982234-24794D06-7CA7-4F85-96BC-271C5BC6386BQ96143524-4801BABD-3448-4433-8B79-4CF46D456E85
P767
Q61894188-D6FDF5DA-3E70-4157-97A6-39E9860CDE93Q61894219-E38D85E3-FF3E-472F-B8C7-A71C50EBB310Q61894339-1DFF6080-E2C1-4399-8CE2-B08BB2E38206Q61904923-03E9C5A4-B117-494A-8022-1E9C80DB1194Q61907881-D075F0A3-5F9C-41BD-B78D-9CF2C62E8D7EQ61909443-C20B50D5-9D25-49E9-A8AF-B6865ED40B37Q61914670-CD856096-90E6-4154-A4C0-2E4E4D65CAFAQ61914676-C75F5C2F-81A3-49AF-BA33-A73F7A852B87Q61914692-B523E373-E8C1-4E1F-897C-A63D497D3F2AQ61914791-C8E0A29C-A459-4477-B298-32A8F6E8828FQ61915071-EF5CCAA7-E3C3-49E8-9D11-37156C726ABEQ61915346-82CC08A2-7C6D-4759-B3D2-94E32AE5FDF3Q61915370-389D890B-962E-4068-9E1C-620980018188Q61915375-C34D509C-8CF5-4C52-AA8C-72BAFC4AB31FQ61915379-1C2D90A9-1A6B-4226-9C21-3A9A9A8C104DQ61915381-BD119390-3F18-4638-8DA5-8673ADCB22C8Q61915392-302D2AEB-69FC-4F59-9707-76D641269222Q61917457-A3D70A44-BFBB-478B-B09A-B1EEED159EDCQ61917464-4054ED50-7725-45CB-B21E-B43A6F039118Q61917474-289470FB-A37D-4930-AE47-D93A935635DEQ61917494-EB622728-3CEE-40C1-8A20-676FEEB3A696Q61917496-0860DBE0-2BA7-488D-BF17-623E49EEF5A6Q61917515-2A6A0819-2BDD-46C6-AFBA-10D6B702C6AEQ61917518-73274A53-56B5-4786-B047-F37CC6090439Q61917768-85F15F29-C13D-4EDC-A0AD-315E556FD25EQ61917941-93677006-77B4-475C-B306-13C7BED012E7Q61917962-8835AEC5-4CE4-49F6-9EAF-8CD4F0B4F0DDQ61918152-DBB17AAC-7DDA-4018-863D-BA67D8C7BC33Q61918177-5355F576-1EAE-4C63-B875-DE882F68BB6BQ61918400-B97E5624-A38D-4907-9690-C572F64C26ADQ61918482-E15BCF7E-CCF9-4656-8C54-9130FFEB89D8Q61920826-BF70CD45-D64E-4631-B066-ABAB1C5ABFACQ61920964-A6461C6C-FE7F-40FD-846F-FE4E04457916Q61920998-0344AE5E-2134-4C8A-8FFB-68931D63C947Q61921119-77646060-A949-446D-B31B-A479FC46E826Q61921121-ADFEB0FD-C2A5-4853-82E5-B5DC920F07BBQ61921536-47C2F542-6B02-4A3E-9C9A-5DC1924FCF6DQ61921571-C525627D-145E-4E51-BD9E-F33AC69917A6Q61921592-81C1BD36-DBBE-4DAF-B8BD-38716B59BF75Q61921605-B04D76CD-FEBF-4FBF-B30E-337733B7B90C
P859
description
Czech company
@en
bedrijf uit Tsjechië
@nl
česká společnost
@cs
name
Merck Sharp & Dohme
@ca
Merck Sharp & Dohme
@cs
Merck Sharp & Dohme
@en
Merck Sharp & Dohme
@fr
type
label
Merck Sharp & Dohme
@ca
Merck Sharp & Dohme
@cs
Merck Sharp & Dohme
@en
Merck Sharp & Dohme
@fr
altLabel
Merck Sharp & Dohme s.r.o.
@cs
Merck Sharp & Dohme s.r.o.
@en
prefLabel
Merck Sharp & Dohme
@ca
Merck Sharp & Dohme
@cs
Merck Sharp & Dohme
@en
Merck Sharp & Dohme
@fr
P1448
Merck Sharp & Dohme s.r.o.
@cs
P159
P4156
P571
2008-09-18T00:00:00Z